Gilead Sciences
Gilead Sciences

Dividends • Gilead Sciences

GILD

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

See below the complete and updated table with all dividends paid and declared history, etc

Excluding Date
Payment
Value ($)
Frequency
6/13/2025
6/27/2025
0,79
Quarterly
3/14/2025
3/28/2025
0,79
Quarterly
12/13/2024
12/30/2024
0,77
Quarterly
9/13/2024
9/27/2024
0,77
Quarterly
6/14/2024
6/27/2024
0,77
Quarterly
4/15/2024
4/24/2024
1,36
Quarterly
3/14/2024
3/28/2024
0,77
Quarterly
12/14/2023
12/28/2023
0,75
Quarterly
11/21/2023
12/5/2023
1,46
Quarterly
9/14/2023
9/28/2023
0,75
Quarterly
8/28/2023
9/12/2023
1,5
Quarterly
6/14/2023
6/29/2023
0,75
Quarterly
5/22/2023
6/6/2023
1,46
Quarterly
3/24/2023
4/5/2023
2,59
Quarterly
3/14/2023
3/30/2023
0,75
Quarterly
12/14/2022
12/29/2022
0,73
Quarterly
1/3